These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

323 related articles for article (PubMed ID: 24362411)

  • 1. Short-term combined treatment with liraglutide and metformin leads to significant weight loss in obese women with polycystic ovary syndrome and previous poor response to metformin.
    Jensterle Sever M; Kocjan T; Pfeifer M; Kravos NA; Janez A
    Eur J Endocrinol; 2014 Mar; 170(3):451-9. PubMed ID: 24362411
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Short term monotherapy with GLP-1 receptor agonist liraglutide or PDE 4 inhibitor roflumilast is superior to metformin in weight loss in obese PCOS women: a pilot randomized study.
    Jensterle M; Salamun V; Kocjan T; Vrtacnik Bokal E; Janez A
    J Ovarian Res; 2015 Jun; 8():32. PubMed ID: 26032655
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Postpartum treatment with liraglutide in combination with metformin versus metformin monotherapy to improve metabolic status and reduce body weight in overweight/obese women with recent gestational diabetes: A double-blind, randomized, placebo-controlled study.
    Elkind-Hirsch KE; Shaler D; Harris R
    J Diabetes Complications; 2020 Apr; 34(4):107548. PubMed ID: 32046931
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A 12-week treatment with the long-acting glucagon-like peptide 1 receptor agonist liraglutide leads to significant weight loss in a subset of obese women with newly diagnosed polycystic ovary syndrome.
    Jensterle M; Kravos NA; Pfeifer M; Kocjan T; Janez A
    Hormones (Athens); 2015; 14(1):81-90. PubMed ID: 25885106
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Liraglutide increases IVF pregnancy rates in obese PCOS women with poor response to first-line reproductive treatments: a pilot randomized study.
    Salamun V; Jensterle M; Janez A; Vrtacnik Bokal E
    Eur J Endocrinol; 2018 Jul; 179(1):1-11. PubMed ID: 29703793
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dipeptidyl Peptidase-4 Inhibitor Sitagliptin Prevented Weight Regain in Obese Women with Polycystic Ovary Syndrome Previously Treated with Liraglutide: A Pilot Randomized Study.
    Ferjan S; Janez A; Jensterle M
    Metab Syndr Relat Disord; 2017 Dec; 15(10):515-520. PubMed ID: 29064743
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Short-term effectiveness of low dose liraglutide in combination with metformin versus high dose liraglutide alone in treatment of obese PCOS: randomized trial.
    Jensterle M; Kravos NA; Goričar K; Janez A
    BMC Endocr Disord; 2017 Jan; 17(1):5. PubMed ID: 28143456
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Metformin as an initial adjunct to low-dose liraglutide enhances the weight-decreasing potential of liraglutide in obese polycystic ovary syndrome: Randomized control study.
    Jensterle M; Goricar K; Janez A
    Exp Ther Med; 2016 Apr; 11(4):1194-1200. PubMed ID: 27073422
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Short-term intervention with liraglutide improved eating behavior in obese women with polycystic ovary syndrome.
    Jensterle M; Kocjan T; Kravos NA; Pfeifer M; Janez A
    Endocr Res; 2015; 40(3):133-8. PubMed ID: 25330463
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Short-term effect of beinaglutide combined with metformin versus metformin alone on weight loss and metabolic profiles in obese patients with polycystic ovary syndrome: a pilot randomized trial.
    Wen Q; Fang S; Liang Y; Tian Y; Chen Y; Yuan J; Chen Q
    Front Endocrinol (Lausanne); 2023; 14():1156521. PubMed ID: 37347114
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of metformin versus metformin plus liraglutide on gonadal and metabolic profiles in overweight patients with polycystic ovary syndrome.
    Xing C; Zhao H; Zhang J; He B
    Front Endocrinol (Lausanne); 2022; 13():945609. PubMed ID: 36060969
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Short-term combined treatment with exenatide and metformin for overweight/obese women with polycystic ovary syndrome.
    Ma RL; Deng Y; Wang YF; Zhu SY; Ding XS; Sun AJ
    Chin Med J (Engl); 2021 Nov; 134(23):2882-2889. PubMed ID: 34732660
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Low dose of liraglutide combined with metformin leads to a significant weight loss in Chinese Han women with polycystic ovary syndrome: a retrospective study.
    Long X; Liu H; Xiong W; Li W; He H; Fu T; Li X; Chen C; Zhang L; Liu Y
    Gynecol Endocrinol; 2023 Jun; 39(1):2223648. PubMed ID: 37406658
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Short-term exenatide treatment leads to significant weight loss in a subset of obese women without diabetes.
    Dushay J; Gao C; Gopalakrishnan GS; Crawley M; Mitten EK; Wilker E; Mullington J; Maratos-Flier E
    Diabetes Care; 2012 Jan; 35(1):4-11. PubMed ID: 22040840
    [TBL] [Abstract][Full Text] [Related]  

  • 15. GLP-1 Receptor Agonist Treatment Increases Bone Formation and Prevents Bone Loss in Weight-Reduced Obese Women.
    Iepsen EW; Lundgren JR; Hartmann B; Pedersen O; Hansen T; Jørgensen NR; Jensen JE; Holst JJ; Madsbad S; Torekov SS
    J Clin Endocrinol Metab; 2015 Aug; 100(8):2909-17. PubMed ID: 26043228
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Genetic variability in GLP-1 receptor is associated with inter-individual differences in weight lowering potential of liraglutide in obese women with PCOS: a pilot study.
    Jensterle M; Pirš B; Goričar K; Dolžan V; Janež A
    Eur J Clin Pharmacol; 2015 Jul; 71(7):817-24. PubMed ID: 25991051
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A comparison of adding liraglutide versus a single daily dose of insulin aspart to insulin degludec in subjects with type 2 diabetes (BEGIN: VICTOZA ADD-ON).
    Mathieu C; Rodbard HW; Cariou B; Handelsman Y; Philis-Tsimikas A; Ocampo Francisco AM; Rana A; Zinman B;
    Diabetes Obes Metab; 2014 Jul; 16(7):636-44. PubMed ID: 24443830
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phosphodiesterase 4 inhibition as a potential new therapeutic target in obese women with polycystic ovary syndrome.
    Jensterle M; Kocjan T; Janez A
    J Clin Endocrinol Metab; 2014 Aug; 99(8):E1476-81. PubMed ID: 24823465
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Liraglutide: New Perspectives for the Treatment of Polycystic Ovary Syndrome.
    Papaetis GS; Filippou PK; Constantinidou KG; Stylianou CS
    Clin Drug Investig; 2020 Aug; 40(8):695-713. PubMed ID: 32583294
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacologic therapy to induce weight loss in women who have obesity/overweight with polycystic ovary syndrome: a systematic review and network meta-analysis.
    Wang FF; Wu Y; Zhu YH; Ding T; Batterham RL; Qu F; Hardiman PJ
    Obes Rev; 2018 Oct; 19(10):1424-1445. PubMed ID: 30066361
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.